Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AD109 in OSA patients taking GLP-1s
NCT06400615Phase 2Completed
- Sponsor
- Apnimed, Inc.
- Start
- May 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of AD109 in obstructive sleep apnea (OSA), sponsored by Apnimed, Inc.. Started May 2024; status: completed.
02
Drugs
AD109
03
Conditions
obstructive sleep apnea (OSA)
Beyond the preview
Go deeper on NCT06400615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06400615.